Celgene:

Gilead:

Example:

REQUIRED RATIOS FOR FINAL PROJECT SUBMISSION 1. Earnings per Share of Common Stock 2. Current Ratio Net Income: Net income and per common share amounts for the years ended December 31, 2016, 2015 and 2014 were as follows (dollar amounts in millions, except per share data) 2016 2015 2014 Net income 1,999.2 $ 1,602.0 $ 1,999.9 Per common share amounts 2.02 $ 1.94 S Basic 2.57 S 2.49 S 2.49 Diluted 2.39 Weighted average shares 792.2 824.9 Basic 802.7 Diluted 803.3 836.0 The S397.2 million increase in net income to $1.999 billion in 2016 compared to 2015 was primarily due to a higher level of net product sales and a S601.9 million reduction in collaboration-related expenses, partly offset by increases in other expenses, including $892.9 million of research and development asset acquisition expense associated with the purchases of EngMab, Acetylon and Triphase, S345.3 million of increased impairment charges related to strategic equity investments, which included $272.2 million related to our equity investment in Juno, an increase in selling, general and administrative expenses primarily due to a $198.5 million litigation-related loss contingency accrual expense, and an S83.1 million impairment charge related to the technology platform obtained in our 2012 acquisition of Avila GILEAD SCIENCES, INC Consolidated Statements of Cash Flows (in millions) Year Ended December 31 2016 2014 Operating Activides: 13,488 S 18,106 S 12,059 Adjustments to reconcile net income to net cash providad by operating activities Depeeciation expamse Amortiation expense Stock-based compansation expense Excss tax benelits from stock-hasad compasaion Tax benefits from evercise and vesting of stock-basad awands Deferred income taxes In-process resach and developmant impaiment 125 981 937 (194 (585) (482) 393 (236) 101 Changes in operating asds and liabilities Accounts recaivable, nd 1,397) (2,578) (855) Prepaid expenses and other Accounts payable Income taxas payable Acarued liabilitias Delemad revenues 520 371) 2,013 304 Net cash providad by operating activitios 20,329 Investing Activities: Purchases of marketable securiti Proceeds from sales of marketable scunties Poceds from maturities of maketable securitios Other invstmants Capital axpenditures (17,239) 25,619 13,039 1,700 4,792 807 748) (557) Net cash used in invasting ativities (12,475) (1,823) Financing Activides Procceds from debt financing, nd of issuance costs Proceeds rom convertible note hedges Purchases of convertible note hedges Poceds from issuances of common tock Repurdhases of common stock Repayments of debt and other osligations Payments to satle warrants Excess tax banelits from stock-based compensation 9,902 2,343 (11,001) (5,349) (4,779) (4,093) 482 (10,002) 1,981 3, 865) 585 (101) Payment of dividands Contibutions from (distribution to) noncontrolling int ast (2.455 (1,874) 188 35 Net cash used in finanding activities Effact of achunge ate changas on cash and csh equivalnts Net dhange in cash and cash aquivalents Cash and cash equivaants at begiming of penod Cash and csh equivdants at end of period 9,347 4,963 (3,025) (67) 4,622 2,824 12,851 8,229 S 12,851 S Supplemental disdosure of cash fow infomation: Interest paid, net of amounts capitdizal Income taxes paid 2,436 S 3,137S 2,060 See accompanying notes GILEADSCIENCES, INC 24431